References:
1.
Montalescot,
G., et al. . 2013 ESC guidelines on the management of stable
coronary artery disease: the Task Force on the management of stable
coronary artery disease of the European Society of Cardiology. EUR
HEART J 34 , 2949-3003 (2013).
2.
Falase,
B., Easaw, J. & Youhana, A. The role of nicorandil in the treatment of
myocardial ischaemia. Expert Opin Pharmacother 2 ,
845-856 (2001).
3.
Krumenacker,
M. & Roland, E. Clinical profile of nicorandil: an overview of its
hemodynamic properties and therapeutic efficacy. J Cardiovasc
Pharmacol 20 Suppl 3 , S93-S102 (1992).
4.
Refaie,
M., Shehata, S., El-Hussieny, M., Abdelraheem, W.M. & Bayoumi, A. Role
of ATP-Sensitive Potassium Channel (KATP) and eNOS in Mediating the
Protective Effect of Nicorandil in Cyclophosphamide-Induced
Cardiotoxicity. CARDIOVASC TOXICOL 20 , 71-81 (2020).
5.
Taira,
N. Similarity and dissimilarity in the mode and mechanism of action
between nicorandil and classical nitrates: an overview. J
Cardiovasc Pharmacol 10 Suppl 8 , S1-S9 (1987).
6.
Roland,
E. Safety profile of an anti-anginal agent with potassium channel
opening activity: an overview. EUR HEART J 14 Suppl B ,
48-52 (1993).
7.
Walker,
A., et al. . Economic evaluation of the impact of nicorandil in
angina (IONA) trial. HEART 92 , 619-624 (2006).
8.
Horinaka,
S., et al. . Effects of nicorandil on cardiovascular events in
patients with coronary artery disease in the Japanese Coronary Artery
Disease (JCAD) study. CIRC J 74 , 503-509 (2010).
9.
Ferrari,
R., et al. . Anti-anginal drugs-beliefs and evidence: systematic
review covering 50 years of medical treatment. EUR HEART J40 , 190-194 (2019).
10.
Shi,
L., Chen, L., Qi, G., Tian, W. & Zhao, S. Effects of Intracoronary
Nicorandil on Myocardial Microcirculation and Clinical Outcomes in
Patients with Acute Myocardial Infarction: A Meta-Analysis of Randomized
Controlled Trials. Am J Cardiovasc Drugs 20 , 191-198
(2020).
11.
Kasama,
S., et al. . Long-term nicorandil therapy improves cardiac
sympathetic nerve activity after reperfusion therapy in patients with
first acute myocardial infarction. J NUCL MED 48 ,
1676-1682 (2007).
12.
Ito,
H., et al. . Intravenous nicorandil can preserve microvascular
integrity and myocardial viability in patients with reperfused anterior
wall myocardial infarction. J AM COLL CARDIOL 33 ,
654-660 (1999).
13.
Ueda,
H., et al. . Intravenous nicorandil can reduce the occurrence of
ventricular fibrillation and QT dispersion in patients with successful
coronary angioplasty in acute myocardial infarction. CAN J
CARDIOL 20 , 625-629 (2004).
14.
Falase,
B., Easaw, J. & Youhana, A. The role of nicorandil in the treatment of
myocardial ischaemia. Expert Opin Pharmacother 2 ,
845-856 (2001).
15.
Waldron,
G.J. & Cole, W.C. Activation of vascular smooth muscle K+ channels by
endothelium-derived relaxing factors. Clin Exp Pharmacol Physiol26 , 180-184 (1999).
16.
Iwaki,
F., Amano, H. & Ohura, K. Nicorandil inhibits osteoclast
differentiation in vitro. EUR J PHARMACOL 793 , 14-20
(2016).
17.
Li,
W., Wu, N., Shu, W., Jia, D. & Jia, P. Pharmacological preconditioning
and postconditioning with nicorandil attenuates
ischemia/reperfusion-induced myocardial necrosis and apoptosis in
hypercholesterolemic rats. EXP THER MED 10 , 2197-2205
(2015).
18.
Lee,
J.M., et al. . Safety and efficacy of intracoronary nicorandil as
hyperaemic agent for invasive physiological assessment: a patient-level
pooled analysis. EUROINTERVENTION 12 , e208-e215 (2016).
19.
Shirakabe,
A., et al. . Efficacy and safety of nicorandil therapy in patients
with acute heart failure. J CARDIOL 56 , 339-347 (2010).